Skip to main content
SpringerLink
Log in

Mechanisms of tamoxifen resistance

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to bestimulated by tamoxifen just as they are by estrogens. In both animal models and clinical specimens, we have found lower tamoxifen uptake and somewhat altered tamoxifen metabolism in resistant tumors, but neither appears to explain tamoxifen stimulation of the resistant tumors. Nor do estrogen receptor losses or mutations appear to explain this phenomenon, although altered expression of transcriptional variant forms of the receptor may well contribute. Pure steroidal antiestrogens such as ICI 182,780 are capable of reversing tamoxifen-stimulated as well as estrogen-stimulated growth of these resistant tumors, and are now in clinical trials for this purpose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, systemic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1–14, 71–85, 1992

    Google Scholar 

  2. Saez RA, Osborne CK: Hormonal treatment of advanced breast cancer. In: Kennedy BJ (ed) Current Clinical Oncology. Alan R Liss Inc, New York, 1989, pp 163–172

    Google Scholar 

  3. Fujimoto N, Katzenellenbogen BS: Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen-selectivity and promoter-dependence. Mol Endocrinol, in press, 1993.

  4. Encarnación CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SAW, Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237–246, 1993

    Google Scholar 

  5. Pritchard KI, Thomson DB, Myers RE, Sutherland JA, Mobbs BG, Meaken JW: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787–796, 1980

    Google Scholar 

  6. Hoogstraten B, Gad-el-Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M: Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer 54:2248–2256, 1984

    Google Scholar 

  7. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189–1196, 1987

    Google Scholar 

  8. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: Correlation with reduced tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477–1482, 1991

    Google Scholar 

  9. Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183–5187, 1988

    Google Scholar 

  10. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW: Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10:990–994, 1992

    Google Scholar 

  11. Wakeling AE: Steroidal pure antiestrogens.In: Lippman M, Dickson R (eds) Regulatory Mechanisms in Breast Cancer. Kluwer, Boston, 1991, pp 239–257

    Google Scholar 

  12. Parker MG: Action of “pure” antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 26:131–137, 1993

    Google Scholar 

  13. Osborne CK, Jarman M, McCague R, Coronado EB, DeGregorio MW, Hilsenbeck SG, Wakeling AE: The importance of tamoxifen metabolism in tamoxifenstimulated breast tumor growth. Cancer Chemother Pharmacol, in press

  14. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW: Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10:304–310, 1992

    Google Scholar 

  15. Dowsett M, Johnston SRD, Haynes BP, Sacks NPM, Caum MB, Ebbs SR, Smith IE: Impaired intra-tumoral uptake as a mechanism for resistance in human breast cancer. Proc Am Assoc Cancer Res 34:1463 (Abstract), 1993

    Google Scholar 

  16. Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51:104–109, 1991

    Google Scholar 

  17. Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52:483–486, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center, 7703 Floyd Curl Drive, 78284-7884, San Antonio, Texas, USA

    C. Kent Osborne & Suzanne A. W. Fuqua

Authors
  1. C. Kent Osborne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzanne A. W. Fuqua
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osborne, C.K., Fuqua, S.A.W. Mechanisms of tamoxifen resistance. Breast Cancer Res Tr 32, 49–55 (1994). https://doi.org/10.1007/BF00666205

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666205

Key words

Search

Navigation